Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
52 participants
INTERVENTIONAL
2013-11-30
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Pediatric subjects between the ages of 7 - 18 years and adults from the age of 19 years of age upwards, who currently use an insulin pump in the management of their type 1 or type 2 diabetes, will be invited to participate. Each subject will be trained on the study device and then use it for approximately four weeks. During this time there will be three in-clinic visits and four follow-up phone calls, scheduled at the subjects' convenience. At the end of this period, they will revert back to their original insulin pump and complete a questionnaire on the study pump training materials, features and usability.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
User Evaluation of the MiniMed 620G and 640G Insulin Pumps
NCT01726621
Study of MiniMed™ 640G Insulin Pump With SmartGuard™ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes
NCT02733991
United Kingdom User Evaluation, MiniMed Paradigm® X54 System
NCT01267175
Prevention of Hypoglycaemia With Predictive Insulin Suspend Using Sensor Augmented Insulin Pump in Children
NCT02179281
Study of Insulin Pump in Prevention of Low Glucose Events in Adults With Type 1 Diabetes at Risk of Severe Hypoglycemia
NCT02657213
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diabetic participants with study devices
MiniMed® 640G Insulin Pump and Guardian® Link Transmitter
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MiniMed® 640G Insulin Pump and Guardian® Link Transmitter
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject is current insulin pump user for at least 3 months
3. Subject has the following CGM experience as determined by the Investigator:
* Has experience and is able to insert/change sensor by herself/himself and
* Has experience and can recharge the transmitter and
* Has experience and can read sensor data in real-time on her/his pump screen
4. Subject/legal representative has signed a Patient Informed Consent and is willing to comply with the study procedures;
5. Subject is willing to complete study questionnaires throughout the study
6. Must have the following clinical diagnosis:
1\. Type 1 diabetes, for a minimum of 6 months prior to enrollment
Criteria for Exclusion: A subject is excluded from the user evaluation if any of the following criteria are met:
1. Female subject has a positive urine pregnancy screening test.
2. Female subject who plans to become pregnant during the course of study. If a woman becomes pregnant during participation, she will be withdrawn
3. Subject has any condition that, in the opinion of the Investigator or qualified Investigational Centre staff, may preclude him/her from participating in the study and completing study related procedures.
4. Subject has impaired vision or hearing problems that could compromise the handling of the device as determined by Investigator or qualified Investigational Centre staff
5. Subject is unable to tolerate tape adhesive in the area of sensor placement
6. Subject has any unresolved adverse skin condition in the area of sensor placement (e.g. psoriasis, rash, Staphylococcus infection)
7. Subject has travel plans which would make it difficult for the subject to attend on-site study visits as scheduled
7 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medtronic Diabetes
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Vincent Hospital and The University of Melbourne
Fitzroy, , Australia
The Royal Melbourne Hospital
Patkville, , Australia
University College Hospital
London, , United Kingdom
King's College London
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CEP284
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.